Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019
Coronavirus disease 2019 is a major threat to public health globally. Though its pathogenesis has not been fully elucidated, angiotensin-converting enzyme 2 (ACE2) has been recently identified as a receptor for the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the cell....
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-06-01
|
| Series: | Chronic Diseases and Translational Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2095882X20300426 |
| _version_ | 1818470327541301248 |
|---|---|
| author | Meng-Yuan Liu Bo Zheng Yan Zhang Jian-Ping Li |
| author_facet | Meng-Yuan Liu Bo Zheng Yan Zhang Jian-Ping Li |
| author_sort | Meng-Yuan Liu |
| collection | DOAJ |
| description | Coronavirus disease 2019 is a major threat to public health globally. Though its pathogenesis has not been fully elucidated, angiotensin-converting enzyme 2 (ACE2) has been recently identified as a receptor for the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the cell. Here, we aimed to clarify the potential role of ACE2 in SARS-CoV-2-induced acute lung injury and its underlying mechanism. As a receptor for coronavirus, ACE2 mediates the entry of SARS-CoV-2 into cells in a similar way as for severe acute respiratory syndrome coronavirus (SARS-CoV). The high binding affinity of SARS-CoV-2 to ACE2 correlates with its efficient spread among humans. On the other hand, ACE2 negatively regulates the renin-angiotensin-aldosterone system (RAAS) primarily by converting angiotensin II to angiotensin 1–7, which exerts a beneficial effect on coronavirus-induced acute lung injury. Human recombinant ACE2 has been considered as a potential therapy for SARS-CoV-2 by blocking virus entry and redressing the imbalance of RAAS in SARS-CoV-2 infection. The level of ACE2 expression can be upregulated by treatment with an ACE inhibitor (ACEI) or angiotensin Ⅱ type 1 receptor blocker (ARB). To date, no evidence shows that ACEIs or ARBs increase the susceptibility and mortality of patients infected with SARS-CoV-2, and hence, it is not advisable to discontinue such drugs in patients with cardiovascular disease. |
| first_indexed | 2024-04-13T21:35:53Z |
| format | Article |
| id | doaj.art-206b816da909444199c0f4f7c34d5205 |
| institution | Directory Open Access Journal |
| issn | 2095-882X |
| language | English |
| last_indexed | 2024-04-13T21:35:53Z |
| publishDate | 2020-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Chronic Diseases and Translational Medicine |
| spelling | doaj.art-206b816da909444199c0f4f7c34d52052022-12-22T02:28:58ZengWileyChronic Diseases and Translational Medicine2095-882X2020-06-016298105Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019Meng-Yuan Liu0Bo Zheng1Yan Zhang2Jian-Ping Li3Department of Cardiology, Peking University First Hospital, Beijing 100034, China; NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100034, China; Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, Health Science Center, Peking University, Beijing 100034, ChinaDepartment of Cardiology, Peking University First Hospital, Beijing 100034, China; NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100034, China; Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, Health Science Center, Peking University, Beijing 100034, ChinaDepartment of Cardiology, Peking University First Hospital, Beijing 100034, China; NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100034, China; Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, Health Science Center, Peking University, Beijing 100034, ChinaDepartment of Cardiology, Peking University First Hospital, Beijing 100034, China; NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100034, China; Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, Health Science Center, Peking University, Beijing 100034, China; Corresponding author. Department of Cardiology, Peking University First Hospital, Beijing 100034, China.Coronavirus disease 2019 is a major threat to public health globally. Though its pathogenesis has not been fully elucidated, angiotensin-converting enzyme 2 (ACE2) has been recently identified as a receptor for the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the cell. Here, we aimed to clarify the potential role of ACE2 in SARS-CoV-2-induced acute lung injury and its underlying mechanism. As a receptor for coronavirus, ACE2 mediates the entry of SARS-CoV-2 into cells in a similar way as for severe acute respiratory syndrome coronavirus (SARS-CoV). The high binding affinity of SARS-CoV-2 to ACE2 correlates with its efficient spread among humans. On the other hand, ACE2 negatively regulates the renin-angiotensin-aldosterone system (RAAS) primarily by converting angiotensin II to angiotensin 1–7, which exerts a beneficial effect on coronavirus-induced acute lung injury. Human recombinant ACE2 has been considered as a potential therapy for SARS-CoV-2 by blocking virus entry and redressing the imbalance of RAAS in SARS-CoV-2 infection. The level of ACE2 expression can be upregulated by treatment with an ACE inhibitor (ACEI) or angiotensin Ⅱ type 1 receptor blocker (ARB). To date, no evidence shows that ACEIs or ARBs increase the susceptibility and mortality of patients infected with SARS-CoV-2, and hence, it is not advisable to discontinue such drugs in patients with cardiovascular disease.http://www.sciencedirect.com/science/article/pii/S2095882X20300426Severe acute respiratory syndrome coronavirus 2Angiotensin-converting enzyme 2Acute lung injury |
| spellingShingle | Meng-Yuan Liu Bo Zheng Yan Zhang Jian-Ping Li Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019 Chronic Diseases and Translational Medicine Severe acute respiratory syndrome coronavirus 2 Angiotensin-converting enzyme 2 Acute lung injury |
| title | Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019 |
| title_full | Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019 |
| title_fullStr | Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019 |
| title_full_unstemmed | Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019 |
| title_short | Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019 |
| title_sort | role and mechanism of angiotensin converting enzyme 2 in acute lung injury in coronavirus disease 2019 |
| topic | Severe acute respiratory syndrome coronavirus 2 Angiotensin-converting enzyme 2 Acute lung injury |
| url | http://www.sciencedirect.com/science/article/pii/S2095882X20300426 |
| work_keys_str_mv | AT mengyuanliu roleandmechanismofangiotensinconvertingenzyme2inacutelunginjuryincoronavirusdisease2019 AT bozheng roleandmechanismofangiotensinconvertingenzyme2inacutelunginjuryincoronavirusdisease2019 AT yanzhang roleandmechanismofangiotensinconvertingenzyme2inacutelunginjuryincoronavirusdisease2019 AT jianpingli roleandmechanismofangiotensinconvertingenzyme2inacutelunginjuryincoronavirusdisease2019 |